Drug Trial Radar · NCT07004075
FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration
Last checked: Nov 19, 2026Latest source record: Jun 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
102
Planned (sponsor's estimate)
Start
Jun 30, 2025
Primary completion
Apr 30, 2027
Study completion Apr 30, 2029
Sponsor
- Lead sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, randomized, multi-center phase III clinical study: Aim to evaluate the efficacy and safety of FCN-159 monotherapy versus the treatment by investigator's choice in patients with pediatric low-grade glioma harboring KIAA1549-BRAF fusion or BRAF V600E mutation
Conditions
- Low-grade Glioma
- Pediatric Low-grade Gliomas
- pLGG With BRAF Alteration
Interventions
LuvometinibDrug
Luvometinib oral tablet
Chemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, TemozolomideBiological
Investigator's choice of chemotherapy administered IV or orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare the progression free survival (PFS) of FCN-159 versus chemotherapy by IRCTime frame: up to 48 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.